These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23535292)

  • 1. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
    Boyd SD; Hadigan C; McManus M; Chairez C; Nieman LK; Pau AK; Alfaro RM; Kovacs JA; Calderon MM; Penzak SR
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):355-61. PubMed ID: 23535292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
    Sekar V; Lavreys L; Van de Casteele T; Berckmans C; Spinosa-Guzman S; Vangeneugden T; De Pauw M; Hoetelmans R
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4440-5. PubMed ID: 20660678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
    Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
    HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
    Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
    Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study.
    Ratner PH; Melchior A; Dunbar SA; Tantry SK; Dorinsky PM
    Clin Ther; 2012 Jun; 34(6):1422-31. PubMed ID: 22621776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
    Blanche S; Bologna R; Cahn P; Rugina S; Flynn P; Fortuny C; Vis P; Sekar V; van Baelen B; Dierynck I; Spinosa-Guzman S
    AIDS; 2009 Sep; 23(15):2005-13. PubMed ID: 19724191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
    Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
    Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma.
    Harrison LI; Kurup S; Wagner C; Ekholm BP; Larson JS; Kaiser HB
    Eur J Clin Pharmacol; 2002 Jun; 58(3):197-201. PubMed ID: 12107606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
    Sekar VJ; Lefebvre E; De Pauw M; Vangeneugden T; Hoetelmans RM
    Br J Clin Pharmacol; 2008 Aug; 66(2):215-21. PubMed ID: 18460033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.